Insider Selling: Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $240,000.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $12.00, for a total value of $240,000.00. Following the sale, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,082,160. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

Shares of DRTS stock opened at $12.58 on Wednesday. The firm has a market capitalization of $1.14 billion, a PE ratio of -18.78 and a beta of 1.19. The firm has a fifty day simple moving average of $9.55 and a two-hundred day simple moving average of $7.74. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical Ltd. has a 12 month low of $2.87 and a 12 month high of $12.61.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts forecast that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DRTS has been the topic of several recent research reports. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. LADENBURG THALM/SH SH boosted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Citigroup increased their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.60.

Institutional Trading of Alpha Tau Medical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical in the 3rd quarter worth about $62,000. Bank of America Corp DE boosted its stake in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Millennium Management LLC bought a new position in shares of Alpha Tau Medical in the third quarter valued at approximately $170,000. Mariner LLC increased its position in shares of Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares during the last quarter. Finally, Apella Capital LLC bought a new stake in Alpha Tau Medical during the fourth quarter worth $1,892,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.